Relmada Therapeutics, Inc. announced the appointment of John Hixon to a newly created position as Head of Commercial. Mr. Hixon has over 36 years of commercial planning and marketing experience within the biopharmaceutical industry. Mr. Hixon's years of broad marketing experience within the biopharmaceutical industry includes a 31-year career with Eli Lilly and Company.

During his tenure at Eli Lilly, Hixon was most recently Senior Director for Global New Product Planning – Biomedicines, where Mr. Hixon worked side-by-side with discovery and early phase development scientists and physicians. Hixon was also the commercialization representative for the Lilly Research Laboratories early phase governance committees. Within the same role, Mr. Hixon was actively involved in numerous business development projects by delivering the commercialization position for these efforts.

Prior to his Global New Product Planning role, Mr. Hixon held numerous marketing leadership roles with Lilly in the United States, Spain, South Korea, and Australia. Hixon and his teams launched Zyprexa (antipsychotic medication) in Australia, led the late lifecycle global marketing and repositioning effort for Prozac (antidepressant medicine), and launched Cymbalta in the U.S. for both major depressive disorder (MDD) and diabetic peripheral neuropathic pain. After Lilly, he founded Salt Creek Biosciences as a new product planning and commercialization consulting company.

Mr. Hixon received a bachelor's degree in economics from DePauw University and an MBA from the University of Miami (Coral Gables, Florida).